References to accompany the March 2018 issue of  Kai Tiaki Nursing New Zealand

1. Jauch, E., Al Kasab, S. & Stettler, B. (2018). Ischemic stroke. Medscape Drugs & Diseases. https://emedicine.medscape.com/article/1916852-overview#a1
2. WHO: World Health Organisation. (2011). Global atlas on cardiovascular disease prevention and control. World Health Organisation: Geneva.
3. Feigin, V. et al. (2014). Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. The Lancet. 383(9913): 245-254.
4. WHO. (2017). Cardiovascular diseases (CVDs). Fact sheet. Accessed February 2018. http://www.who.int/mediacentre/factsheets/fs317/en/
5. Stroke Association UK. (2018). State of the nation: stroke statistics. February 2018. https://www.stroke.org.uk/system/files/sotn_2018.pdf
6. Lapchak, P. & Zhang, J. (2017). The high cost of stroke and stroke cryoprotection research. Translational Stroke research. 8(94): 307-317.
7. Australian Bureau of Statistics. (2017). Causes of death in Australia. http://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/3303.0~2015~Main%20Features~Stroke~10003
8. Deloitte Access Economics. (2013). The economic impact of stroke in Australia. National Stroke Foundation.
9. Feigin, V. et al. (2015). 30-year trends in stroke rates and outcome in Auckland, New Zealand (1981-2012): A multi-ethnic population-based series of studies. PLoS One. 10(8): e0134609.
10. Thrift, A. et al. (2017). Global stroke statistics. International Journal of Stroke. 12(1): 13-32.
11. Ministry of Health (2009). Report on New Zealand Cost-of-Illness Studies on Long-Term Conditions. Wellington: Ministry of Health. 
12. Patel, A. et al. (2017). Executive summary part 2: Burden of stroke in the next 20 years and potential returns from increased spending on research. Stroke Association UK. https://www.stroke.org.uk/sites/default/files/costs_of_stroke_in_the_uk_report_-executive_summary_part_2.pdf
13. Mozaffarian, D. et al. (2016). Executive summary: heart disease and stroke statistics—2016 update. Circulation. 133: 447-454.
14. Cordonnier, C. et al. (2017). Stroke in women—from evidence to inequalities. Nature Reviews Neurology. 13: 521-532.
15. Liebeskind, D. (2017). Hemorrhagic stroke. Medscape Drugs & Diseases. https://emedicine.medscape.com/article/1916662-overview
16. Boss, B. & Huether, S. (2014). Disorders of the central and peripheral nervous systems and the neuromuscular junction. In McCance, K. & Huether, S. (eds.). Pathophysiology: The biological basis of disease in adults and children. (7^th ed.). Mosby Elsevier.
17. Moyter, R. et al. (2018). Current evidence for endovascular therapy in stroke and remaining uncertainties. Journal of Internal Medicine.  283(1): 2-15.
18. Choudhury, G. & Ding, S. (2016). Reactive astrocytes and therapeutic potential in focal ischaemic stroke. Neurobiology of Disease.  85(1): 234-244.
19. Fothergill, R. et al. (2013). Does the use of the Recognition Of Stroke In the Emergency Room stroke assessment tool enhance stroke recognition by ambulance clinicians? Stroke. 44: 3007-3012.
20. Lyden, P. (2017). Using the National Institutes of Health Stroke Scale. Stroke. 48(2). http://stroke.ahajournals.org/content/strokeaha/early/2017/01/11/STROKEAHA.116.015434.full.pdf
21. Caidilhac, D. et al. (2017): Risk-adjusted hospital mortality rates for stroke: evidence from the Australian Stroke Clinical Registry. Medical Journal of Australia. 206(8): 345-350.
22. Hankey, G. (2017). Assessing the outcome of stroke in Australia. Medical Journal of Australia. 206(8): 343-344.
23. Bruno-Petrina, A. Motor recovery in stroke. Medscape Drugs & Diseases. https://emedicine.medscape.com/article/324386-overview
24. Winstein, C. et al. (2016). Guidelines for adult stroke rehabilitation and recovery. A guideline for healthcare professional from the American Heart Association/American Stroke Association. Stroke. 47: e98-e169.
25. Joundi, R. et al. (2017). Predictors and outcomes of dysphagia screening after acute ischemic stroke. Stroke. 48(3): http://stroke.ahajournals.org/content/early/2017/03/08/STROKEAHA.116.015332
26. Smith, E. et al. (2018). Effect of dysphagia screening strategies on clinical outcomes after stroke: a systematic review for the 2018 Guidelines for the Early Management of Patients with Acute Ischaemic Stroke. Stroke. 49(3): DOI: 10.1161/ STR.0000000000000159 
27. Daemerschalk, B. et al. (2016). Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke. 47(2): 581-641.
28. Hacke, W. et al. (2018). Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: individual -patient-data meta-analysis of randomized trials. International Journal of Stroke. 13(2): 175-189.
29. Stroke Foundation of New Zealand and New Zealand Guidelines Group. (2010). Clinical Guidelines for Stroke Management 2010. Wellington: Stroke Foundation of New Zealand. 
30. Stroke Foundation of Australia. (2017). Clinical guidelines for stroke management 2017. https://informme.org.au/Guidelines/Clinical-Guidelines-for-Stroke-Management-2017
31. Target: Stroke II. (2017). Introducing Target: Stroke phase II. American Heart Association American Stroke Association. http://www.strokeassociation.org/STROKEORG/Professionals/TargetStroke/Target-Stroke-Phase-II_UCM_469859_Article.jsp#.WnPCFVT1XUI
32. Fink, J. (2017). Improvements in acute stroke treatments in New Zealand—no one should be left behind. New Zealand Medical Journal. 130(1453): 6-7.
33. Stroke Foundation of Australia (2017). National Stroke Audit 2017. https://informme.org.au/en/stroke-data/Acute-audits
34. Zhai, S. et al. (2017). The cost-effectiveness of Stroke Unit in providing enhanced patients outcomes in an Australian teaching hospital. Journal of Stroke and Cerebrovascular Diseases. 26(10): 2326-2368.
35. Child, N. et al. (2012). New Zealand national acute stroke services audit: acute stroke care delivery in New Zealand. The New Zealand Medical Journal. 125(1358): 44-51.
36. Graham, C. et al. (2017). The FOCUS, AFINITY and EFFECTS trials studying the effect(s) of fluoxetine  in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials. 18(1): article No. 627.
37. Aroor, S., Singh, R. & Goldstein, L. (2017). BE-FAST (Balance , eyes, face, arms, speech, time): reducing the proportion of strokes missed using the FAST Mnemonic. Stroke. 48(1). http://stroke.ahajournals.org/content/early/2017/01/12/STROKEAHA.116.015169
38. Scheitz, J. et al. (2017). Clinical selection strategies to identify ischemic stroke patients with large anterior vessel occlusion. Stroke. 48(2). http://stroke.ahajournals.org/content/strokeaha/early/2017/01/13/STROKEAHA.116.014431.full.pdf
39. Evans, M et al. (2018). Acute or delayed systemic administration of human amnion epithelial cells improves outcomes in experimental stroke. Stroke. 49(1): https://doi.org/10.1161/STROKEAHA.117.019136